Bleeding

Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024

Retrieved on: 
Tuesday, April 2, 2024
Research, Biotechnology, Disease, Paratriathlon, Patient, Ageing, ARVO, Quality of life, Life expectancy, Retina, Bleeding, Pharmacokinetics, AMD, NAMD, Annual general meeting

Age-related macular degeneration (AMD) is a leading cause of severe vision loss and blindness for people aged 60 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals.

Key Points: 
  • Age-related macular degeneration (AMD) is a leading cause of severe vision loss and blindness for people aged 60 years and older in developed countries worldwide, with a profound impact on the quality of life of affected individuals.
  • With the increase in life expectancy, the number of reported cases of AMD is increasing.
  • The disease and its current treatment regimen add significant burden on patients, caretakers, and on health care system.
  • nAMD accounts for roughly 10% of all AMD cases, but almost 90% of AMD-related central vision loss.

Olympus Announces FDA Clearance of RenaFlex™, Its First Single-use Flexible Ureteroscope

Retrieved on: 
Tuesday, April 2, 2024
System, U.S. FDA, Burns, Urology, Small Business Saturday, Lithotripsy, Endoscopy, Risk, Patient, Perforation, Infection, Health professional, Bleeding, Ureteroscopy, Kidney, Ureter, Urethra, Physician, Medical imaging

CENTER VALLEY, Pa., April 2, 2024 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later date.

Key Points: 
  • The RenaFlex single-use flexible ureteroscope system is used to access and visualize the urinary tract to diagnose and treat urinary diseases and disorders, such as kidney stones.
  • The RenaFlex ureteroscope can be used with endotherapeutic accessories to perform diagnostic and therapeutic procedures within the urinary tract.
  • The RenaFlex Single-use Ureteroscope works in combination with the compatible CV-S1 Video System Center for flexible Single-use Endoscopes.
  • Visit the urology product page for more information about the complete line of Olympus urology solutions.

China Medical University Hospital Develops "AISIA" to Diagnose Acute Ischemic Stroke in 90 Seconds to Assist Doctors in Making Medical Decisions

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, Control, Stroke, Blood pressure, Speech, Brain, Pneumonia, Brain ischemia, Kidney, NCCT, Physician, Paralysis, Risk, External carotid artery, Patient, Contrast-induced nephropathy, Cerebrovascular disease, Mortality, Long-term care, Death, Judgement, Deep learning, Nausea, Atherosclerosis, Bleeding, Heart, Neurology, Agent handling, Ministry, Shadow, CTP, Vomiting, Artificial intelligence, Rehabilitation, Dysarthria

The models analyze NCCT and CTP images to detect acute ischemic stroke, as well as to identify the ischemic core and penumbra.

Key Points: 
  • The models analyze NCCT and CTP images to detect acute ischemic stroke, as well as to identify the ischemic core and penumbra.
  • This assist physicians in making decision of acute ischemic stroke management.
  • This system can determine the presence of acute ischemic stroke in approximately 90 seconds.
  • In this way, the facilitated AISIA platform means a lot for ischemic stroke patients and medical experts as well.

Knix announces Gabrielle Union as Global Brand Ambassador and debuts a new brand tagline "Knix For Life."

Retrieved on: 
Wednesday, March 27, 2024
Gabrielle Union, KNIX-FM, Bleeding, Partnership, Life, Perspiration, Acquisition, Rizzoli, Woman, Essity, Multimedia, Human, Mobile phone

Knix will debut this partnership with their new campaign and tagline "Knix for Life."

Key Points: 
  • Knix will debut this partnership with their new campaign and tagline "Knix for Life."
  • Gabrielle Union becomes Knix's newest Global Brand Ambassador since their $400M acquisition by Essity in September 2022.
  • "I'm proud to be working with a brand like Knix," says Gabrielle Union.
  • Gabrielle Union's commitment to authenticity is without compromise, and her values to be her genuine self make her the perfect Knix Brand Ambassador.

Olympus Partners with American Lung Association on Patient Education for Lung Cancer Screening

Retrieved on: 
Wednesday, March 27, 2024
Diagnosis, Biopsy, Lung cancer, Medicine, Immunotherapy, Disease, Infection, Partnership, Patient, Sore throat, Perforation, Cancer, United, Olympus Corporation, Senior, Lymph, Bleeding, EUS, American Lung Association, Physician, Medical imaging

CENTER VALLEY, Pa., March 27, 2024 /PRNewswire/ -- Olympus Corporation of the Americas, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, is now partnering with the American Lung Association to educate lung cancer patients about the care pathway for diagnosing and staging lung nodules.

Key Points: 
  • The lung nodules educational resources , sponsored by Olympus, help patients understand the diagnosis and staging process for lung nodules and why it is important to their treatment journey.
  • "Olympus is very excited to support this great new educational resource for lung cancer patients through our partnership with the American Lung Association," said Jovan Reyerson, Senior Vice President of Medical and Scientific Affairs at Olympus Corporation of the Americas.
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), a procedure pioneered by Olympus, has helped lay the groundwork for targeted cancer treatment such as immunotherapy.
  • Lung cancer remains the leading cause of cancer death in the United States.² Early detection of lung cancer is key as the 5-year relative survival rate for non-small cell lung cancer is about 65% when caught at a localized stage.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS®

Retrieved on: 
Tuesday, March 26, 2024
Ulcer, Myocardial infarction, Liver disease, Endo International, Hyperkalemia, Horizon Therapeutics, Patient, Stroke, History, Aspirin, CABG, Pain, Famotidine, Itch, NSAID, Stomach, Central nervous system, Edema, ACE, Risk, CNS, Perforation, Peptic ulcer disease, Heart failure, Anaphylaxis, Amgen, Fatigue, Hypertension, Delirium, Kidney, Coma, Tablet, Eosinophilia, Nonsteroidal anti-inflammatory drug, Senior, Rash, Lethargy, OTC, Creatinine, Hepatotoxicity, Ibuprofen, Hypersensitivity, Esophagus, Jaundice, Rheumatoid arthritis, Water retention, Seizure, Incidence, Gastrointestinal bleeding, Inflammation, Extrapyramidal system, Ischemia, Diarrhea, GI, Nausea, Diuretic, Bleeding, NSAIDS, Physician, Osteoarthritis, Pharmaceutical industry

DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.

Key Points: 
  • DUBLIN, March 26, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., launched ibuprofen-famotidine 800 mg/26.6 mg tablets, a generic version of Amgen's (formerly Horizon Therapeutics) DUEXIS®.
  • Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at a greater risk for serious GI events.
  • Ibuprofen and famotidine tablets should not be administered to patients with a history of hypersensitivity to other H2-receptor antagonists.
  • If ibuprofen and famotidine is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

More hysterectomies can be averted with earlier uterine artery embolization for postpartum hemorrhage

Retrieved on: 
Saturday, March 23, 2024
Health, Postpartum bleeding, Hysterectomy, Uterus, Internal bleeding, Uterine artery embolization, Incidence, Abdominal pain, Patient, Uncontrolled, Research, Bleeding, University, Society, Artery, Woman, Treatment, Blood, Birth control

FAIRFAX, Va., March 23, 2024 /PRNewswire/ -- Early intervention with a minimally invasive treatment called uterine artery embolization (UAE) can help women avoid hysterectomy due to severe bleeding after childbirth, according to a new study being presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City.

Key Points: 
  • The study was a retrospective review of 66 patients (median age, 31) who underwent UAE for uncontrolled postpartum hemorrhage at a single, high-volume medical center between 2014 and 2022.
  • Postpartum hemorrhage is a rare but potentially deadly complication of childbirth.
  • The study found that it was more likely to occur in patients who experienced greater blood loss before embolization.
  • Abstract #189 : Short-Term and Long-Term Outcomes of Uterine Artery Embolization for Treatment of Uncontrolled Post-Partum Hemorrhage.

First Skeleton-Wide Study of Blood Cell Formation Yields Surprising Findings

Retrieved on: 
Wednesday, March 20, 2024
Humerus, Cell, Bone marrow, Infection, Disease, Bleeding, Laser, Mechanics, Anatomy, Mouse, Research, Nature, Experimental Hematology, Doctor of Philosophy, Femur, Human, Sternum, Arteriole, Neutrophil, Blood, G-CSF, Division, Marker beacon, Tibia, Skull, Skeleton, Ageing, Vaccine

CINCINNATI, March 20, 2024 /PRNewswire/ -- Imagine being able to count the different types of blood cells being formed inside the tiny bones of a mouse and pinpointing the strings and clusters of cells within the bone marrow that are responsible for producing specific types of blood cells.

Key Points: 
  • "Meanwhile, efforts to stimulate production of certain blood cell types may be dramatically improved by focusing on specific bone types."
  • The key discoveries reported in the paper include:
    New tools allowing visualization of blood production inside the bone, allowing defining the basic anatomy of blood cell formation.
  • Among several examples: blood loss triggered rapid red blood cell production in the sternum, tibia, vertebrae, and humerus -- but not in the skull.
  • Importantly, the process developed for this study allowed the team to analyze blood cell development in multiple parts of the skeleton.

Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

Retrieved on: 
Tuesday, March 19, 2024
Medicine, Cervical cancer, Patient, Cancer, HPV16, School, Congress, Gynaecology, Risk, Peking Union Medical College, Woman, LEEP, Safety, Gynecologic Oncology (journal), Pathology, Recurrence, Squamous intraepithelial lesion, Acceleration, Research, Șaeș, SGO, Death, National Cancer Center, Vaccination, Molina Healthcare, Annual general meeting, Health, Obstetrics, Hysterectomy, HSIL, Public health, Infection, Incidence, LSIL, HPV, Bleeding, Physician, Birth control

This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.

Key Points: 
  • This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL.
  • Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment.
  • The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
  • Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, "We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702.